Quantcast
Last updated on April 18, 2014 at 10:45 EDT

Latest Management of atrial fibrillation Stories

2014-04-02 08:32:43

MUNICH, Germany, April 2, 2014 /PRNewswire/ -- For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a five-fold increased risk of stroke compared with the general population[2] Daiichi Sankyo today announced its commitment to extend the PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). The extension of the registry will include a specific...

2014-03-31 08:28:47

First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion PARSIPPANY, N.J., March 31, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor...

2014-03-04 16:25:59

Results Published in Nursing 2014 Show that Self-testing Protocol Reduced Out-of-Range Coagulation Test Results and Need for Clinic Follow-up WALTHAM, Mass., March 4, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, today announced the results of a study demonstrating that at-home coagulation testing among...

2014-02-04 12:26:39

The Quest Diagnostics Health Trends(TM) study of 2.7 million test results is the largest to examine warfarin treatment in patients with atrial fibrillation (Afib) treated in primary care and other non-hospital care settings in the United States MADISON, N.J., Feb. 4, 2014 /PRNewswire/ -- Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy,...

2013-11-21 08:27:13

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 21, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a publication titled, Pharmacological Cardioversion of Atrial Fibrillation with Vernakalant: Evidence in Support of the ESC Guidelines, was published in Europace, the official Journal of the European Heart Rhythm Association, and was made available in the advanced online article access section. The authors conclude that BRINAVESS is an efficacious...

2013-10-28 20:24:51

BERLIN, October 29, 2013 /PRNewswire/ -- Atrial fibrillation is an under-diagnosed, undertreated abnormal heart rhythm that increases stroke risk five-fold compared to the general population World Stroke Day 2013 By World Stroke Day 2013 (October 29) more than 500,000 people have shown their support for the Sign Against Stroke in Atrial Fibrillation campaign, calling for urgent coordinated action to avoid the thousands of preventable strokes that...

2013-10-08 10:40:34

Lone atrial fibrillation in children has substantial symptomatic burden and recurrence rate say researchers in the Canadian Journal of Cardiology Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated heart disease), researchers found a nearly 40% recurrence rate and that AF in the young is accompanied by substantial...

2013-10-07 08:26:03

NASDAQ: CRME TSX: COM VANCOUVER, Oct. 7, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced publication of positive data from an observational, retrospective study performed at the Skane University Hospital in Malmö, Sweden. The study included 251 recent-onset atrial fibrillation (AF) patients who received 355 BRINAVESS(TM) treatments during the period between January 15, 2011 and April 15, 2013. During the observation period, 70% of the AF...

2013-10-02 08:30:57

Data published in Circulation show trend towards lower mortality, despite the lack of a specific reversal agent for dabigatran RIDGEFIELD, Conn., Oct. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a retrospective analysis comparing clinical management and patient outcomes following a major bleeding event during treatment with dabigatran or warfarin. The findings show that outcomes after a major bleed on dabigatran were not worse than after a...

2013-09-03 12:26:34

-- GARFIELD Registry presentations at ESC CONGRESS 2013 provide outcomes data on real-world treatment patterns of at-risk AF populations -- AMSTERDAM, Sept. 3, 2013 /PRNewswire/ -- One-year outcomes data from the first cohort of the Global Anticoagulant Registry in the FIELD (GARFIELD), an innovative, independent academic research initiative, provide insights into the elevated stroke risk among subpopulations of patients with atrial fibrillation (AF). The findings, from eight abstracts...